These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32944203)

  • 1. Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality.
    Hyldgaard C; Møller J; Bendstrup E
    Eur Clin Respir J; 2020 Aug; 7(1):1807682. PubMed ID: 32944203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics of idiopathic pulmonary fibrosis patients with gender, age, and physiology staging at Okinawa Chubu Hospital.
    Kishaba T; Shimaoka Y; Fukuyama H; Nagano H; Nei Y; Yamashiro S; Tamaki H
    J Thorac Dis; 2015 May; 7(5):843-9. PubMed ID: 26101639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
    Yıldırım F; Türk M; Bitik B; Erbaş G; Köktürk N; Haznedaroğlu Ş; Türktaş H
    Kaohsiung J Med Sci; 2019 Jun; 35(6):365-372. PubMed ID: 30913371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry.
    Gao J; Kalafatis D; Carlson L; Pesonen IHA; Li CX; Wheelock Å; Magnusson JM; Sköld CM
    Respir Res; 2021 Feb; 22(1):40. PubMed ID: 33546682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].
    Sun D; Cheng Z; Jiang TC; Li PF; Jia LQ; Wang TT; Zheng CP; Li Y; Duo MJ
    Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(10):748-752. PubMed ID: 32192286
    [No Abstract]   [Full Text] [Related]  

  • 7. Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?
    Nurmi HM; Purokivi MK; Kärkkäinen MS; Kettunen HP; Selander TA; Kaarteenaho RL
    BMC Pulm Med; 2017 Jan; 17(1):16. PubMed ID: 28086844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple breath washout: A new and promising lung function test for patients with idiopathic pulmonary fibrosis.
    Nyilas S; Schreder T; Singer F; Poellinger A; Geiser TK; Latzin P; Funke M
    Respirology; 2018 Aug; 23(8):764-770. PubMed ID: 29573509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
    Hyldgaard C
    Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.
    Morisset J; Vittinghoff E; Lee BY; Tonelli R; Hu X; Elicker BM; Ryu JH; Jones KD; Cerri S; Manfredi A; Sebastiani M; Gross AJ; Ley B; Wolters PJ; King TE; Kim DS; Collard HR; Lee JS
    Respir Med; 2017 Jun; 127():51-56. PubMed ID: 28502419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum human epididymis protein 4 is associated with disease severity and worse survival in idiopathic pulmonary fibrosis: a cohort study.
    Tian M; Meng K; Gao Y; Zhang J; Xie M; Tian Y; Liu X; Ma M; Cai Y; Wu H; Ding J; Chen J; Cai H
    Ann Transl Med; 2022 Sep; 10(18):992. PubMed ID: 36267722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.
    Jo HE; Glaspole I; Moodley Y; Chapman S; Ellis S; Goh N; Hopkins P; Keir G; Mahar A; Cooper W; Reynolds P; Haydn Walters E; Zappala C; Grainge C; Allan H; Macansh S; Corte TJ
    BMC Pulm Med; 2018 Jan; 18(1):19. PubMed ID: 29370786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year.
    Collins BF; Spiekerman CF; Shaw MA; Ho LA; Hayes J; Spada CA; Stamato CM; Raghu G
    Chest; 2017 Jul; 152(1):103-112. PubMed ID: 28300570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative CT analysis of honeycombing area predicts mortality in idiopathic pulmonary fibrosis with definite usual interstitial pneumonia pattern: A retrospective cohort study.
    Nakagawa H; Ogawa E; Fukunaga K; Kinose D; Yamaguchi M; Nagao T; Tanaka-Mizuno S; Nakano Y
    PLoS One; 2019; 14(3):e0214278. PubMed ID: 30897161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of Idiopathic Pulmonary Fibrosis from Connective Tissue Disease-Related Interstitial Lung Disease Using Quantitative Imaging.
    Chung JH; Adegunsoye A; Cannon B; Vij R; Oldham JM; King C; Montner SM; Thirkateh P; Barnett S; Karwoski R; Bartholmai BJ; Strek M; Nathan SD
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34204184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis.
    Lassenius MI; Toppila I; Pöntynen N; Kasslin L; Kaunisto J; Kilpeläinen M; Laitinen T
    Eur Clin Respir J; 2020; 7(1):1702618. PubMed ID: 32002175
    [No Abstract]   [Full Text] [Related]  

  • 17. [
    Justet A; Laurent-Bellue A; Thabut G; Dieudonné A; Debray MP; Borie R; Aubier M; Lebtahi R; Crestani B
    Respir Res; 2017 Apr; 18(1):74. PubMed ID: 28449678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different Faces of Idiopathic Pulmonary Fibrosis With Preserved Forced Vital Capacity.
    Bermudo G; Suarez-Cuartin G; Rivera-Ortega P; Rodriguez-Portal JA; Sauleda J; Nuñez B; Castillo D; Aburto M; Portillo K; Balcells E; Badenes-Bonet D; Valenzuela C; Fernandez-Fabrellas E; González-Budiño T; Cano E; Acosta O; Leiro-Fernández V; Romero A; Planas-Cerezales L; Villar A; Moreno A; Laporta R; Vicens-Zygmunt V; Shull J; Franquet T; Luburich P; Molina-Molina M
    Arch Bronconeumol; 2022 Feb; 58(2):135-141. PubMed ID: 33895005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.
    Durheim MT; Bendstrup E; Carlson L; Sutinen EM; Hyldgaard C; Kalafatis D; Myllärniemi M; Sköld CM; Sjåheim T
    Respirology; 2021 Oct; 26(10):982-988. PubMed ID: 34291523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.